BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

...2Q20 action date and would mark the first FDA approval for non-alcoholic steatohepatitis. RVL-201 from Osmotica Pharmaceuticals plc...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...hemoglobinuria (see “Apellis Readies to Compete with Soliris” ). Separately, Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Osmotica Pharmaceuticals plc...
...ADSs on NASDAQ. BioCentury Staff Emergex Vaccines Holdings Ltd. TScan Therapeutics Inc. Omniome Inc. Hinova Pharmaceuticals Inc. Apellis Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. Osmotica Pharmaceuticals plc...
BioCentury | May 7, 2019
Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

...difficulties with sleep onset and/or sleep maintenance. Osmotica planning 3Q NDA for droopy eyelid therapy Osmotica Pharmaceuticals plc...
...Assistant Editor ACD855 ACD856 Belsomra, suvorexant (MK-4305) Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) AlzeCure Pharma AB AstraZeneca plc Merck & Co. Inc. Osmotica Pharmaceuticals plc RVL-1201...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...HKEX:1801) 10/24/18 $484.6 $2,056.9 $3,550.2 73% LogicBio Therapeutics Inc. (NASDAQ:LOGC) 10/18/18 $80.5 $229.9 $239.1 4% Osmotica Pharmaceuticals plc...
BioCentury | Nov 30, 2018
Financial News

Centrexion steps back from IPO amid volatile market

...priced at the low end of its range with the same number of shares and Osmotica Pharmaceuticals plc...
BioCentury | Nov 17, 2018
Financial News

Centrexion steps back from IPO amid volatile market

...priced at the low end of its range with the same number of shares and Osmotica Pharmaceuticals plc...
BioCentury | Oct 26, 2018
Financial News

LogicBio joins PhaseBio, Osmotica in missing IPO price target

...Blair and Chardan. Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc...
BioCentury | Oct 19, 2018
Financial News

LogicBio marks week’s third IPO to miss price target

...Blair and Chardan. Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc...
BioCentury | Oct 19, 2018
Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

...Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced...
...see "Paper Chase" ). PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS), Malvern, Pa. Osmotica Pharmaceuticals plc (NASDAQ:OSMT), Bridgewater, N.J. Paul Bonanos PB2452 (MEDI2452) Osmotica Pharmaceuticals plc PhaseBio...
BioCentury | Oct 18, 2018
Financial News

PhaseBio, Osmotica price IPOs well below range

...Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced...
Items per page:
1 - 10 of 11
BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

...2Q20 action date and would mark the first FDA approval for non-alcoholic steatohepatitis. RVL-201 from Osmotica Pharmaceuticals plc...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...hemoglobinuria (see “Apellis Readies to Compete with Soliris” ). Separately, Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Osmotica Pharmaceuticals plc...
...ADSs on NASDAQ. BioCentury Staff Emergex Vaccines Holdings Ltd. TScan Therapeutics Inc. Omniome Inc. Hinova Pharmaceuticals Inc. Apellis Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. Osmotica Pharmaceuticals plc...
BioCentury | May 7, 2019
Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

...difficulties with sleep onset and/or sleep maintenance. Osmotica planning 3Q NDA for droopy eyelid therapy Osmotica Pharmaceuticals plc...
...Assistant Editor ACD855 ACD856 Belsomra, suvorexant (MK-4305) Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) AlzeCure Pharma AB AstraZeneca plc Merck & Co. Inc. Osmotica Pharmaceuticals plc RVL-1201...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...HKEX:1801) 10/24/18 $484.6 $2,056.9 $3,550.2 73% LogicBio Therapeutics Inc. (NASDAQ:LOGC) 10/18/18 $80.5 $229.9 $239.1 4% Osmotica Pharmaceuticals plc...
BioCentury | Nov 30, 2018
Financial News

Centrexion steps back from IPO amid volatile market

...priced at the low end of its range with the same number of shares and Osmotica Pharmaceuticals plc...
BioCentury | Nov 17, 2018
Financial News

Centrexion steps back from IPO amid volatile market

...priced at the low end of its range with the same number of shares and Osmotica Pharmaceuticals plc...
BioCentury | Oct 26, 2018
Financial News

LogicBio joins PhaseBio, Osmotica in missing IPO price target

...Blair and Chardan. Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc...
BioCentury | Oct 19, 2018
Financial News

LogicBio marks week’s third IPO to miss price target

...Blair and Chardan. Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc...
BioCentury | Oct 19, 2018
Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

...Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced...
...see "Paper Chase" ). PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS), Malvern, Pa. Osmotica Pharmaceuticals plc (NASDAQ:OSMT), Bridgewater, N.J. Paul Bonanos PB2452 (MEDI2452) Osmotica Pharmaceuticals plc PhaseBio...
BioCentury | Oct 18, 2018
Financial News

PhaseBio, Osmotica price IPOs well below range

...Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced...
Items per page:
1 - 10 of 11